Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BECTON DICKINSON & COBDX · Entity 2498 | Director | January 25, 2022 | January 26, 2022 |
| Embecta Corp.EMBC · Entity 5950 | Director | February 11, 2026 | February 13, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BECTON DICKINSON & CO
Report date January 25, 2022 · Filed January 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,982 |
Reported balance
After 2022-01-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-25 · Grant · Acquired 820 · Balance 9,982 F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.
F2: Includes units acquired through dividend reinvestment since the last report filed by the reporting person.
Embecta Corp.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,127.164 |
Reported balance
After 2026-02-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 22,841 · Balance 66,127.164 F1: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends.
HAEMONETICS CORP
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,410 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,538 · Balance 19,410 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2026 Filed Jul 28, 2026 21:00 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000109 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,410 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 23:20 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 22,841 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-26-000161 · ownership.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,127.164 F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 20:33 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019598 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,872 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:18 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 13,839 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-25-000185 · ownership.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,289.153 F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:23 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,207 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021034 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,179 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:05 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 11,455 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-24-000105 · ownership.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,443.858 F1 · balance_after: The number of shares reported in Column 5 of Table I includes shares received by the reporting person as stock dividends. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022205 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,972 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 21:12 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 6,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008335 · doc4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,631.6279 F1 · balance_after: The number of shares reported in Column 5 of Table I have been reduced by 451 shares to reflect the correct number of Embecta shares received as dividends in connection with Embecta's spinoff from Becton, Dickinson and Company ("BD") on April 1, 2022. F2 · balance_after: The number of shares reported in Column 5 of Table I now includes 82.627912 shares received by the reporting person as stock dividends. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:43 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020702 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,746 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:03 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 6,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023273 · doc4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,021 Read SEC document |
| January 25, 2022 Filed Jan 26, 2022 18:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-001585 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,982 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:30 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023397 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,016 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 15:02 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 829 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-21-000012 · edgar.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,956 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 21:40 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-021993 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,939 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 16:02 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 765 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-20-000017 · edgar.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,096 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:37 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-025271 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| April 29, 2019 Filed May 1, 2019 21:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-016753 · form4.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 14:38 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-19-000005 · edgar.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,242 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 14:32 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 941 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-18-000010 · edgar.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,237 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 19:16 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001543407-17-000009 · edgar.xml · nonDerivative · entry 1 Pomeroy Claire · CIK 0001603648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,221 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.